Salvianolic Acid B
Treatment-Resistant Depression (TRD)
PreclinicalActive
Key Facts
About atai Life Sciences
atai Life Sciences aims to transform mental health treatment by leveraging a decentralized platform to accelerate the development of psychedelic-inspired therapeutics. The company's strategy involves identifying, incubating, and advancing a diverse pipeline of drug candidates, primarily targeting treatment-resistant depression and other high-need conditions. As a public company, atai has raised significant capital to fund its clinical programs and has established collaborations with leading scientific institutions. Its approach combines novel compounds with digital therapeutics and data analytics to address the global mental health crisis.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SPN-820/821 | Supernus Pharmaceuticals | Phase 2 |
| BHV-2100 (mGluR2/3 NAM) | Biohaven | Phase 1 |
| PCN-101 (R-ketamine) | atai Life Sciences | Phase 2 |
| VLS-01 (DMT) | atai Life Sciences | Phase 1 |
| GH001 | GH Research | Phase 2b |
| BMB-101 | Bright Minds Biosciences | Phase 2 |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 1/2 |
| CYC-126 | Cyclerion Therapeutics | Phase 2 |